dc.contributor.author | Schaller, UC | |
dc.contributor.author | Walli, RK | |
dc.contributor.author | Mueller, AJ | |
dc.contributor.author | Klauss, V | |
dc.date.accessioned | 2013-06-18T12:39:22Z | |
dc.date.available | 2013-06-18T12:39:22Z | |
dc.date.issued | 1999 | |
dc.identifier.citation | Ophthalmologe. 1999 Dec;96(12):829-31. | en |
dc.identifier.uri | http://hinari-gw.who.int/whalecomwww.ncbi.nlm.nih.gov/whalecom0/pubmed/10643318 | |
dc.identifier.uri | http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/35653 | |
dc.description.abstract | BACKGROUND:
The purpose of this study was to evaluate the course of CMV retinitis after initiation of highly active antiretroviral therapy (HAART) and discontinuation of systemic anti-CMV maintenance therapy.
PATIENTS AND METHODS:
Case reports are presented for two AIDS patients (2 eyes, ages 34, 43, male) with CMV retinitis. The CD4 count at the time of CMV retinitis was 20/microliter (patient 1) and 35/microliter (patient 2). Under HAART the CD4 count rose up to 202/microliter (patient 1) and 350/microliter (patient 2); the viral load was under detection limit in both patients. At that time systemic maintenance therapy was discontinued in both patients.
RESULTS:
There was no progression of retinitis during the observation period of 21 months (patient 1) and 24 months (patient 2).
CONCLUSIONS:
In selected patients with immune recovery under HAART it is possible to discontinue systemic anti-CMV maintenance therapy. | en |
dc.title | Regression of cytomegalovirus retinitis in AIDS patients without systemic maintenance anti-cytomegalovirus therapy treated with highly active antiretroviral therapy | en |
dc.type | Article | en |
local.publisher | Department of Ophthalmology, College of Health Sciences, University of Nairobi | en |